{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T15:17:46Z","timestamp":1794755866104,"version":"4.9.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005895","name":"Fred Hutchinson Cancer Research Center","doi-asserted-by":"publisher","award":["Vaccine and Infectious Disease Division Faculty Initiative"],"award-info":[{"award-number":["Vaccine and Infectious Disease Division Faculty Initiative"]}],"id":[{"id":"10.13039\/100005895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005895","name":"Fred Hutchinson Cancer Research Center","doi-asserted-by":"publisher","award":["Evergreen Beyond Pilot Award"],"award-info":[{"award-number":["Evergreen Beyond Pilot Award"]}],"id":[{"id":"10.13039\/100005895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01-AI171186"],"award-info":[{"award-number":["R01-AI171186"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Human metapneumovirus (HMPV) is a major cause of respiratory infections, particularly among vulnerable populations, yet effective therapeutics remain unavailable. Monoclonal antibodies (mAbs) offer a promising approach for treatment and prevention. We describe the discovery and characterization of 4F11, a highly potent neutralizing mAb with in vitro and in vivo efficacy against HMPV. Using cryo-electron microscopy, we define a unique mechanism of binding employed by 4F11. 4F11 targets an epitope located at the apex of the prefusion F protein (site \u00d8) with a 1:1 stoichiometry of Fab to trimer, distinct from the 3:1 stoichiometry observed with other HMPV site \u00d8 antibodies. Unlike other site \u00d8 antibodies which penetrate the glycan shield between Asn57 and Asn172, 4F11 binds vertically and directly interacts with the Asn172 glycan. In vitro, 4F11 displays high neutralization potency across diverse HMPV strains. It also shows low propensity for resistance development, with only a single escape mutation (K179E) identified, a mutation not found in any published HMPV sequence to date. Viruses rescued with the K179E escape mutation have significantly decreased fitness in vitro. In male hamsters, 4F11 significantly reduces viral loads in the lungs and nasal turbinates. These findings highlight 4F11 as a promising candidate for therapeutic development.<\/jats:p>","DOI":"10.1038\/s41467-026-69328-w","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T19:44:36Z","timestamp":1770925476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of a potent monoclonal antibody for treatment of human metapneumovirus infections"],"prefix":"10.1038","volume":"17","author":[{"given":"Evelyn D.","family":"Harris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-0098","authenticated-orcid":false,"given":"Morgan","family":"McGovern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-2932","authenticated-orcid":false,"given":"Sara","family":"Pernikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4012-7532","authenticated-orcid":false,"given":"Ren","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Kipnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Sobolik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4260-9784","authenticated-orcid":false,"given":"Matthew","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7443-0527","authenticated-orcid":false,"given":"Alexander L.","family":"Greninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1304-8161","authenticated-orcid":false,"given":"Chen-Ni","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1420-2271","authenticated-orcid":false,"given":"Tong-Ming","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9217-6270","authenticated-orcid":false,"given":"Marie","family":"Pancera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5858-2662","authenticated-orcid":false,"given":"Jim","family":"Boonyaratanakornkit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"69328_CR1","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/S2214-109X(20)30393-4","volume":"9","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob. Health 9, e33\u2013e43 (2021).","journal-title":"Lancet Glob. Health"},{"key":"69328_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2024.100679","volume":"6","author":"D Kulkarni","year":"2025","unstructured":"Kulkarni, D. et al. The global burden of human metapneumovirus-associated acute respiratory infections in older adults: a systematic review and meta-analysis. Lancet Healthy Longev. 6, 100679 (2025).","journal-title":"Lancet Healthy Longev."},{"key":"69328_CR3","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1001\/archinte.168.22.2489","volume":"168","author":"EE Walsh","year":"2008","unstructured":"Walsh, E. E., Peterson, D. R. & Falsey, A. R. Human metapneumovirus infections in adults: another piece of the puzzle. Arch. Intern. Med. 168, 2489\u20132496 (2008).","journal-title":"Arch. Intern. Med."},{"key":"69328_CR4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2209604","volume":"388","author":"A Papi","year":"2023","unstructured":"Papi, A. et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N. Engl. J. Med. 388, 595\u2013608 (2023).","journal-title":"N. Engl. J. Med."},{"key":"69328_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","volume":"388","author":"B Kampmann","year":"2023","unstructured":"Kampmann, B. et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N. Engl. J. Med. 388, 1451\u20131464 (2023).","journal-title":"N. Engl. J. Med."},{"key":"69328_CR6","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","volume":"389","author":"E Wilson","year":"2023","unstructured":"Wilson, E. et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N. Engl. J. Med. 389, 2233\u20132244 (2023).","journal-title":"N. Engl. J. Med."},{"key":"69328_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","volume":"72","author":"M Melgar","year":"2023","unstructured":"Melgar, M. et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices\u2014United States, 2023. MMWR Morb. Mortal. Wkly. Rep. 72, 793\u2013801 (2023).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"69328_CR8","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.bbmt.2017.06.006","volume":"23","author":"LB Kennedy","year":"2017","unstructured":"Kennedy, L. B., Li, Z., Savani, B. N. & Ljungman, P. Measuring immune response to commonly used vaccinations in adult recipients of allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 23, 1614\u20131621 (2017).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"69328_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/bmt.2015.47","volume":"50","author":"A Ambati","year":"2015","unstructured":"Ambati, A. et al. Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study. Bone Marrow Transplant. 50, 858\u2013864 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"69328_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/bmt.2015.49","volume":"50","author":"AE Harris","year":"2015","unstructured":"Harris, A. E. et al. Pretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection? Bone Marrow Transplant. 50, 899\u2013903 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"69328_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1365-2141.2008.07295.x","volume":"143","author":"M Boeckh","year":"2008","unstructured":"Boeckh, M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br. J. Haematol. 143, 455\u2013467 (2008).","journal-title":"Br. J. Haematol."},{"key":"69328_CR12","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1086\/504268","volume":"193","author":"V Erard","year":"2006","unstructured":"Erard, V. et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J. Infect. Dis. 193, 1619\u20131625 (2006).","journal-title":"J. Infect. Dis."},{"key":"69328_CR13","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.bbmt.2013.05.005","volume":"19","author":"C Renaud","year":"2013","unstructured":"Renaud, C. et al. Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. Biol. Blood Marrow Transplant. 19, 1220\u20131226 (2013).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"69328_CR14","doi-asserted-by":"crossref","unstructured":"Agha, R. & Avner, J. R. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics 148, e2021052089 (2021).","DOI":"10.1542\/peds.2021-052089"},{"key":"69328_CR15","doi-asserted-by":"crossref","unstructured":"Foley, D. A. et al. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. Clin. Infect. Dis. 73, e2829\u2013e2830 (2021).","DOI":"10.1093\/cid\/ciaa1906"},{"key":"69328_CR16","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.inf.0000133165.85909.08","volume":"23","author":"X Saez-Llorens","year":"2004","unstructured":"Saez-Llorens, X. et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 23, 707\u2013712 (2004).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"69328_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt, L. L. et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N. Engl. J. Med. 386, 837\u2013846 (2022).","journal-title":"N. Engl. J. Med."},{"key":"69328_CR18","doi-asserted-by":"publisher","first-page":"ofad279","DOI":"10.1093\/ofid\/ofad279","volume":"10","author":"MG Ison","year":"2023","unstructured":"Ison, M. G. et al. Efficacy and safety of adintrevimab (ADG20) for the treatment of high-risk ambulatory patients with mild or moderate coronavirus disease 2019: results from a Phase 2\/3, randomized, placebo-controlled trial (STAMP) conducted during delta predominance and early emergence of omicron. Open Forum Infect. Dis. 10, ofad279 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"69328_CR19","doi-asserted-by":"publisher","first-page":"ofad314","DOI":"10.1093\/ofid\/ofad314","volume":"10","author":"MG Ison","year":"2023","unstructured":"Ison, M. G. et al. Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a Phase 2\/3 randomized, double-blind, placebo-controlled trial (EVADE). Open Forum Infect. Dis. 10, ofad314 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"69328_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162342","volume":"14","author":"S Esposito","year":"2023","unstructured":"Esposito, S. et al. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy. Front. Immunol. 14, 1162342 (2023).","journal-title":"Front. Immunol."},{"key":"69328_CR21","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.antiviral.2018.06.006","volume":"156","author":"E de Wit","year":"2018","unstructured":"de Wit, E. et al. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antivir. Res. 156, 64\u201371 (2018).","journal-title":"Antivir. Res."},{"key":"69328_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186063","volume":"14","author":"M Zorzan","year":"2023","unstructured":"Zorzan, M. et al. Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy. Front. Immunol. 14, 1186063 (2023).","journal-title":"Front. Immunol."},{"key":"69328_CR23","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1086\/314523","volume":"178","author":"R Malley","year":"1998","unstructured":"Malley, R. et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J. Infect. Dis. 178, 1555\u20131561 (1998).","journal-title":"J. Infect. Dis."},{"key":"69328_CR24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1542\/peds.100.6.937","volume":"100","author":"WJ Rodriguez","year":"1997","unstructured":"Rodriguez, W. J. et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 100, 937\u2013942 (1997).","journal-title":"Pediatrics"},{"key":"69328_CR25","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1128\/AAC.31.12.1882","volume":"31","author":"VG Hemming","year":"1987","unstructured":"Hemming, V. G. et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob. Agents Chemother. 31, 1882\u20131886 (1987).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69328_CR26","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1542\/peds.99.3.454","volume":"99","author":"WJ Rodriguez","year":"1997","unstructured":"Rodriguez, W. J. et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 99, 454\u2013461 (1997).","journal-title":"Pediatrics"},{"key":"69328_CR27","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/cid\/ciz697","volume":"70","author":"YK Lim","year":"2020","unstructured":"Lim, Y. K., Kweon, O. J., Kim, H. R., Kim, T. H. & Lee, M. K. Clinical features, epidemiology, and climatic impact of genotype-specific human metapneumovirus infections: long-term surveillance of hospitalized patients in South Korea. Clin. Infect. Dis. 70, 2683\u20132694 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"69328_CR28","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1086\/504260","volume":"193","author":"IM Mackay","year":"2006","unstructured":"Mackay, I. M. et al. Genetic diversity of human metapneumovirus over 4 consecutive years in Australia. J. Infect. Dis. 193, 1630\u20131633 (2006).","journal-title":"J. Infect. Dis."},{"key":"69328_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10409230802058320","volume":"43","author":"JM White","year":"2008","unstructured":"White, J. M., Delos, S. E., Brecher, M. & Schornberg, K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol. 43, 189\u2013219 (2008).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"69328_CR30","doi-asserted-by":"publisher","first-page":"17903","DOI":"10.1073\/pnas.0608678103","volume":"103","author":"SA Connolly","year":"2006","unstructured":"Connolly, S. A., Leser, G. P., Yin, H. S., Jardetzky, T. S. & Lamb, R. A. Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc. Natl. Acad. Sci. USA 103, 17903\u201317908 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69328_CR31","doi-asserted-by":"publisher","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","volume":"7","author":"JO Ngwuta","year":"2015","unstructured":"Ngwuta, J. O. et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci. Transl. Med. 7, 309ra162 (2015).","journal-title":"Sci. Transl. Med."},{"key":"69328_CR32","doi-asserted-by":"crossref","unstructured":"Gilman, M. S. et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol. 1, eaaj1879 (2016).","DOI":"10.1126\/sciimmunol.aaj1879"},{"key":"69328_CR33","doi-asserted-by":"publisher","first-page":"9288","DOI":"10.1073\/pnas.0503989102","volume":"102","author":"HS Yin","year":"2005","unstructured":"Yin, H. S., Paterson, R. G., Wen, X., Lamb, R. A. & Jardetzky, T. S. Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc. Natl. Acad. Sci. USA 102, 9288\u20139293 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69328_CR34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1097\/00006454-199710000-00003","volume":"16","author":"A Moscona","year":"1997","unstructured":"Moscona, A. Interaction of human parainfluenza virus type 3 with the host cell surface. Pediatr. Infect. Dis. J. 16, 917\u2013924 (1997).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"69328_CR35","doi-asserted-by":"publisher","first-page":"e0250780","DOI":"10.1371\/journal.pone.0250780","volume":"16","author":"D Van Egeren","year":"2021","unstructured":"Van Egeren, D. et al. Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. PLoS ONE 16, e0250780 (2021).","journal-title":"PLoS ONE"},{"key":"69328_CR36","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","volume":"22","author":"K Tao","year":"2021","unstructured":"Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757\u2013773 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"69328_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jinf.2023.05.004","volume":"87","author":"M Pinana","year":"2023","unstructured":"Pinana, M. et al. The emergence, impact, and evolution of human metapneumovirus variants from 2014 to 2021 in Spain. J. Infect. 87, 103\u2013110 (2023).","journal-title":"J. Infect."},{"key":"69328_CR38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1743-422X-6-138","volume":"6","author":"CF Yang","year":"2009","unstructured":"Yang, C. F. et al. Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years. Virol. J. 6, 138 (2009).","journal-title":"Virol. J."},{"key":"69328_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111399","volume":"40","author":"SA Rush","year":"2022","unstructured":"Rush, S. A. et al. Characterization of prefusion-F-specific antibodies elicited by natural infection with human metapneumovirus. Cell Rep. 40, 111399 (2022).","journal-title":"Cell Rep."},{"key":"69328_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nsmb.2250","volume":"19","author":"X Wen","year":"2012","unstructured":"Wen, X. et al. Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site. Nat. Struct. Mol. Biol. 19, 461\u2013463 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"69328_CR41","first-page":"84","volume":"8","author":"B Swart","year":"1968","unstructured":"Swart, B. & Dingendorf, W. The effectiveness of X-ray diagnostic examination methods in outflow disorders of the bile ducts with and without jaundice. I. Suprapancreatic bile ducts. Radiologe 8, 84\u201390 (1968).","journal-title":"Radiologe"},{"key":"69328_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36459-3","volume":"14","author":"M Caban","year":"2023","unstructured":"Caban, M. et al. Cross-protective antibodies against common endemic respiratory viruses. Nat. Commun. 14, 798 (2023).","journal-title":"Nat. Commun."},{"key":"69328_CR43","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.immuni.2022.07.003","volume":"55","author":"CG Rappazzo","year":"2022","unstructured":"Rappazzo, C. G. et al. Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein. Immunity 55, 1710\u20131724.e8 (2022).","journal-title":"Immunity"},{"key":"69328_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01708-9","volume":"8","author":"Battles MB","year":"2017","unstructured":"Battles MB et al. Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nat. Commun. 8, 1528 (2017).","journal-title":"Nat. Commun."},{"key":"69328_CR45","doi-asserted-by":"publisher","first-page":"e1011584","DOI":"10.1371\/journal.ppat.1011584","volume":"19","author":"L Ou","year":"2023","unstructured":"Ou, L. et al. Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus. PLoS Pathog. 19, e1011584 (2023).","journal-title":"PLoS Pathog."},{"key":"69328_CR46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2203326119","volume":"119","author":"A Banerjee","year":"2022","unstructured":"Banerjee, A. et al. Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus. Proc. Natl. Acad. Sci. USA 119, e2203326119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69328_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50659-5","volume":"15","author":"MJG Bakkers","year":"2024","unstructured":"Bakkers, M. J. G. et al. Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer. Nat. Commun. 15, 6270 (2024).","journal-title":"Nat. Commun."},{"key":"69328_CR48","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01052-23","volume":"97","author":"X Xiao","year":"2023","unstructured":"Xiao, X. et al. Structural characterization of M8C10, a neutralizing antibody targeting a highly conserved prefusion-specific epitope on the metapneumovirus fusion trimerization interface. J. Virol. 97, e0105223 (2023).","journal-title":"J. Virol."},{"key":"69328_CR49","unstructured":"Cameroni, E., Corti, D., Piccoli, L. & Snell, G. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses. World Intellectual Property Organization. WO\/2024\/026411 (2023). https:\/\/patentscope.wipo.int\/search\/en\/detail.jsf?docId=WO2024026411."},{"key":"69328_CR50","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","volume":"34","author":"J Hadfield","year":"2018","unstructured":"Hadfield, J. et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics 34, 4121\u20134123 (2018).","journal-title":"Bioinformatics"},{"key":"69328_CR51","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1099\/vir.0.2008\/002022-0","volume":"89","author":"S Herfst","year":"2008","unstructured":"Herfst, S. et al. Generation of temperature-sensitive human metapneumovirus strains that provide protective immunity in hamsters. J. Gen. Virol. 89, 1553\u20131562 (2008).","journal-title":"J. Gen. Virol."},{"key":"69328_CR52","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CVI.00230-15","volume":"22","author":"SC Wen","year":"2015","unstructured":"Wen, S. C. & Williams, J. V. New approaches for immunization and therapy against human metapneumovirus. Clin. Vaccin. Immunol. 22, 858\u2013866 (2015).","journal-title":"Clin. Vaccin. Immunol."},{"key":"69328_CR53","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1099\/vir.0.83084-0","volume":"88","author":"S Herfst","year":"2007","unstructured":"Herfst, S. et al. Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J. Gen. Virol. 88, 2702\u20132709 (2007).","journal-title":"J. Gen. Virol."},{"key":"69328_CR54","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1743-422X-5-69","volume":"5","author":"JH Schickli","year":"2008","unstructured":"Schickli, J. H. et al. Deletion of human metapneumovirus M2-2 increases mutation frequency and attenuates growth in hamsters. Virol. J. 5, 69 (2008).","journal-title":"Virol. J."},{"key":"69328_CR55","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.1128\/JVI.78.13.6927-6937.2004","volume":"78","author":"MH Skiadopoulos","year":"2004","unstructured":"Skiadopoulos, M. H. et al. The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J. Virol. 78, 6927\u20136937 (2004).","journal-title":"J. Virol."},{"key":"69328_CR56","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3390\/pathogens3030633","volume":"3","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y., Niewiesk, S. & Li, J. Small animal models for human metapneumovirus: cotton rat is more permissive than hamster and mouse. Pathogens 3, 633\u2013655 (2014).","journal-title":"Pathogens"},{"key":"69328_CR57","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.antiviral.2004.12.009","volume":"66","author":"PR Wyde","year":"2005","unstructured":"Wyde, P. R., Chetty, S. N., Jewell, A. M., Schoonover, S. L. & Piedra, P. A. Development of a cotton rat-human metapneumovirus (hMPV) model for identifying and evaluating potential hMPV antivirals and vaccines. Antivir. Res. 66, 57\u201366 (2005).","journal-title":"Antivir. Res."},{"key":"69328_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.7326\/M21-3507","volume":"175","author":"A-TBS Group","year":"2022","unstructured":"Group, A.-T. B. S. et al. Responses to a neutralizing monoclonal antibody for hospitalized patients with COVID-19 according to baseline antibody and antigen levels: a randomized controlled trial. Ann. Intern. Med. 175, 234\u2013243 (2022).","journal-title":"Ann. Intern. Med."},{"key":"69328_CR59","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","volume":"399","author":"RC Group","year":"2022","unstructured":"Group, R. C. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 399, 665\u2013676 (2022).","journal-title":"Lancet"},{"key":"69328_CR60","doi-asserted-by":"publisher","DOI":"10.1177\/2040206618770518","volume":"26","author":"MS Boukhvalova","year":"2018","unstructured":"Boukhvalova, M. S., Yim, K. C. & Blanco, J. Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus. Antivir. Chem. Chemother. 26, 2040206618770518 (2018).","journal-title":"Antivir. Chem. Chemother."},{"key":"69328_CR61","doi-asserted-by":"crossref","unstructured":"Domachowske, J. et al. Safety and pharmacokinetics of nirsevimab in immunocompromised children. Pediatrics 154, e2024066508 (2024).","DOI":"10.1542\/peds.2024-066508"},{"key":"69328_CR62","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/jcph.2401","volume":"64","author":"L Clegg","year":"2024","unstructured":"Clegg, L., Freshwater, E., Leach, A., Villafana, T. & Hamren, U. W. Population pharmacokinetics of nirsevimab in preterm and term infants. J. Clin. Pharmacol. 64, 555\u2013567 (2024).","journal-title":"J. Clin. Pharmacol."},{"key":"69328_CR63","doi-asserted-by":"crossref","unstructured":"Whaley, R. E. et al. Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies. J. Immunol. Methods 488, 112901 (2020).","DOI":"10.1016\/j.jim.2020.112901"},{"key":"69328_CR64","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1126\/science.1234914","volume":"340","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113\u20131117 (2013).","journal-title":"Science"},{"key":"69328_CR65","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1912884","volume":"13","author":"J Boonyaratanakornkit","year":"2021","unstructured":"Boonyaratanakornkit, J. et al. Protective antibodies against human parainfluenza virus type 3 infection. MAbs 13, 1912884 (2021).","journal-title":"MAbs"},{"key":"69328_CR66","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1073\/pnas.1217537110","volume":"110","author":"JP Julien","year":"2013","unstructured":"Julien, J. P. et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. USA 110, 4351\u20134356 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69328_CR67","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.cell.2019.04.011","volume":"177","author":"S Bangaru","year":"2019","unstructured":"Bangaru, S. et al. A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface. Cell 177, 1136\u20131152 e1118 (2019).","journal-title":"Cell"},{"key":"69328_CR68","doi-asserted-by":"publisher","first-page":"e3000139","DOI":"10.1371\/journal.pbio.3000139","volume":"17","author":"HL Turner","year":"2019","unstructured":"Turner, H. L. et al. Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains. PLoS Biol. 17, e3000139 (2019).","journal-title":"PLoS Biol."},{"key":"69328_CR69","doi-asserted-by":"crossref","unstructured":"Zost, S. J. et al. Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. J. Clin. Investig. 131, e146791 (2021).","DOI":"10.1172\/JCI146791"},{"key":"69328_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28931-3","volume":"13","author":"CL Hsieh","year":"2022","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins. Nat. Commun. 13, 1299 (2022).","journal-title":"Nat. Commun."},{"key":"69328_CR71","doi-asserted-by":"publisher","first-page":"e732","DOI":"10.1016\/S2666-5247(23)00134-9","volume":"4","author":"L Guo","year":"2023","unstructured":"Guo, L., Li, L., Liu, L., Zhang, T. & Sun, M. Neutralising antibodies against human metapneumovirus. Lancet Microbe 4, e732\u2013e744 (2023).","journal-title":"Lancet Microbe"},{"key":"69328_CR72","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/QCO.0000000000000846","volume":"35","author":"J Boonyaratanakornkit","year":"2022","unstructured":"Boonyaratanakornkit, J., Boeckh, M. & Waghmare, A. Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections. Curr. Opin. Infect. Dis. 35, 280\u2013287 (2022).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"69328_CR73","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1099\/vir.0.030049-0","volume":"92","author":"J Zhang","year":"2011","unstructured":"Zhang, J. et al. Effects of N-linked glycosylation of the fusion protein on replication of human metapneumovirus in vitro and in mouse lungs. J. Gen. Virol. 92, 1666\u20131675 (2011).","journal-title":"J. Gen. Virol."},{"key":"69328_CR74","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941\u20131950 (2021).","journal-title":"N. Engl. J. Med."},{"key":"69328_CR75","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108163","volume":"385","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N. Engl. J. Med. 385, e81 (2021).","journal-title":"N. Engl. J. Med."},{"key":"69328_CR76","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","volume":"385","author":"MP O\u2019Brien","year":"2021","unstructured":"O\u2019Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N. Engl. J. Med. 385, 1184\u20131195 (2021).","journal-title":"N. Engl. J. Med."},{"key":"69328_CR77","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm.3443","volume":"20","author":"DJ DiLillo","year":"2014","unstructured":"DiLillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143\u2013151 (2014).","journal-title":"Nat. Med."},{"key":"69328_CR78","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-021-04017-w","volume":"599","author":"R Yamin","year":"2021","unstructured":"Yamin, R. et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 599, 465\u2013470 (2021).","journal-title":"Nature"},{"key":"69328_CR79","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nature12442","volume":"501","author":"D Corti","year":"2013","unstructured":"Corti, D. et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501, 439\u2013443 (2013).","journal-title":"Nature"},{"key":"69328_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2016.272","volume":"2","author":"X Wen","year":"2017","unstructured":"Wen, X. et al. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat. Microbiol. 2, 16272 (2017).","journal-title":"Nat. Microbiol."},{"key":"69328_CR81","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.virol.2003.12.020","volume":"321","author":"S Biacchesi","year":"2004","unstructured":"Biacchesi, S. et al. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology 321, 247\u2013259 (2004).","journal-title":"Virology"},{"key":"69328_CR82","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1126\/science.1243283","volume":"342","author":"JS McLellan","year":"2013","unstructured":"McLellan, J. S. et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342, 592\u2013598 (2013).","journal-title":"Science"},{"key":"69328_CR83","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856\u2013861 (2010).","journal-title":"Science"},{"key":"69328_CR84","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/nprot.2013.117","volume":"8","author":"J Huang","year":"2013","unstructured":"Huang, J. et al. Isolation of human monoclonal antibodies from peripheral blood B cells. Nat. Protoc. 8, 1907\u20131915 (2013).","journal-title":"Nat. Protoc."},{"key":"69328_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10618","volume":"7","author":"AT McGuire","year":"2016","unstructured":"McGuire, A. T. et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat. Commun. 7, 10618 (2016).","journal-title":"Nat. Commun."},{"key":"69328_CR86","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s41592-019-0580-y","volume":"16","author":"D Tegunov","year":"2019","unstructured":"Tegunov, D. & Cramer, P. Real-time cryo-electron microscopy data preprocessing with Warp. Nat. Methods 16, 1146\u20131152 (2019).","journal-title":"Nat. Methods"},{"key":"69328_CR87","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1093\/bioinformatics\/bts480","volume":"28","author":"J Koster","year":"2012","unstructured":"Koster, J. & Rahmann, S. Snakemake-a scalable bioinformatics workflow engine. Bioinformatics 28, 2520\u20132522 (2012).","journal-title":"Bioinformatics"},{"key":"69328_CR88","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"69328_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1618-7","volume":"20","author":"ND Grubaugh","year":"2019","unstructured":"Grubaugh, N. D. et al. An amplicon-based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol. 20, 8 (2019).","journal-title":"Genome Biol."},{"key":"69328_CR90","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. Preprint at https:\/\/ui.adsabs.harvard.edu\/abs\/2013arXiv1303.3997L (2013)."},{"key":"69328_CR91","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1128\/iai.37.1.369-373.1982","volume":"37","author":"RA Johnson","year":"1982","unstructured":"Johnson, R. A., Prince, G. A., Suffin, S. C., Horswood, R. L. & Chanock, R. M. Respiratory syncytial virus infection in cyclophosphamide-treated cotton rats. Infect. Immun. 37, 369\u2013373 (1982).","journal-title":"Infect. Immun."},{"key":"69328_CR92","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/bmt.2015.212","volume":"51","author":"M Boukhvalova","year":"2016","unstructured":"Boukhvalova, M., Blanco, J. C., Falsey, A. R. & Mond, J. Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus. Bone Marrow Transplant. 51, 119\u2013126 (2016).","journal-title":"Bone Marrow Transplant."},{"key":"69328_CR93","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","volume":"368","author":"H Wu","year":"2007","unstructured":"Wu, H. et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652\u2013665 (2007).","journal-title":"J. Mol. Biol."},{"key":"69328_CR94","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/irv.12754","volume":"14","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Severity and mortality of respiratory syncytial virus vs influenza A infection in hospitalized adults in China. Influenza Other Respir. Viruses 14, 483\u2013490 (2020).","journal-title":"Influenza Other Respir. Viruses"},{"key":"69328_CR95","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/cid\/cit471","volume":"57","author":"N Lee","year":"2013","unstructured":"Lee, N. et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin. Infect. Dis. 57, 1069\u20131077 (2013).","journal-title":"Clin. Infect. Dis."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69328-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69328-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69328-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T03:02:14Z","timestamp":1774407734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69328-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69328"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69328-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.B. is an inventor of patent applications filed by Fred Hutchinson Cancer Center directed to the 4F11 and MxR antibodies. S.H., C.-N.C., and T.-M.F. were employees of IgM Biosciences. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2714"}}